

## **Merodis executed the sale of Labima to Vemedica Group.**

*Brussels, Belgium, June 23, 2015*

Merodis, a corporate finance consulting firm serving small and medium sized companies or larger companies pursuing similar sized opportunities, is proud to announce that it advised the selling shareholders of Labima in its sale to Vemedica.

Labima (<http://www.labima.com/>), a Brussels-based pharmaceutical company, occupies a 700 m<sup>2</sup> GMP-approved plant which it uses to provide contract manufacturing services and to produce its own OTC drugs. Over the last years, the company's growth has been primarily driven by the success of its R-Calm Dimenhydrinate® drug in the anti-nausea, vomiting and travel sickness segments. Labima was a family-owned company backed by minority shareholder finance.brussels/group SRIB ([www.finance.brussels](http://www.finance.brussels)).

Vemedica ([www.vemedica.com](http://www.vemedica.com)) is a fast growing consumer health company, marketing leading self-medication brands primarily in selected Western European countries. Vemedica is headquartered in Diemen, the Netherlands and enjoys the #1 position amongst others in its home market. Vemedica has its own operations in 8 countries and employs over 240 people. Vemedica manufactures the majority of its products in its GMP-licensed manufacturing facility, specialized in the production of (film-coated) tablets, sachets and capsules in bottles and blisterpacks.

### **For more information, please contact:**

Rodolphe Blondiau, [rbl@merodis.com](mailto:rbl@merodis.com), +32 488 81 45 07

Dirk Marckx, [dma@merodis.com](mailto:dma@merodis.com), +32 495 38 17 81

### **About Merodis**

We provide middle-market companies with a wide range of financial advisory services in support of mergers, acquisitions, divestitures, capital raising and corporate restructuring. For detailed information concerning the range of services offered, recent transactions and credentials, please consult [www.merodis.com](http://www.merodis.com)

If you no longer wish to receive this information, please send an email with subject "Unsubscribe" to [info@merodis.com](mailto:info@merodis.com). If you want to be informed on new investment opportunities or get the latest news about Merodis, please click <http://www.merodis.com/contact.php?l2=1>